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Abstract
Background The high occurrence and acute and chronic sequelae of traumatic brain injury (TBI) cause major healthcare and
socioeconomic challenges. This study aimed to describe outcome, in-hospital healthcare consumption and in-hospital costs of
patients with TBI.
Methods We used data from hospitalised TBI patients that were included in the prospective observational CENTER-TBI study
in three Dutch Level I Trauma Centres from 2015 to 2017. Clinical data was completed with data on in-hospital healthcare
consumption and costs. TBI severity was classified using the Glasgow Coma Score (GCS). Patient outcome was measured by in-
hospital mortality and Glasgow Outcome Score–Extended (GOSE) at 6 months. In-hospital costs were calculated following the
Dutch guidelines for cost calculation.
Results A total of 486 TBI patients were included. Mean age was 56.1 ± 22.4 years and mean GCS was 12.7 ± 3.8. Six-month
mortality (4.2%–66.7%), unfavourable outcome (GOSE ≤ 4) (14.6%–80.4%) and full recovery (GOSE = 8) (32.5%–5.9%) rates
varied from patients with mild TBI (GCS13–15) to very severe TBI (GCS3–5). Length of stay (8 ± 13 days) and in-hospital costs
(€11,920) were substantial and increased with higher TBI severity, presence of intracranial abnormalities, extracranial injury and
surgical intervention. Costs were primarily driven by admission (66%) and surgery (13%).
Conclusion In-hospital mortality and unfavourable outcome rates were rather high, but many patients also achieved full recovery.
Hospitalised TBI patients show substantial in-hospital healthcare consumption and costs, even in patients with mild TBI. Because
these costs are likely to be an underestimation of the actual total costs, more research is required to investigate the actual costs-
effectiveness of TBI care.
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Introduction
Recent estimates indicate that worldwide up to 69 million
people a year sustain a traumatic brain injury (TBI). [15]
The high incidence of TBI and the associated acute and chron-
ic sequelae cause substantial healthcare and socio-economic
challenges. [32] Available treatments are unfortunately still
largely unproven or unsatisfactory. [9, 15, 32, 75] Patients
suffer from the medical consequences of TBI, which range
from headache and fatigue to severe disabilities and even
death [4, 14, 18, 59, 68]. The total global accompanying costs
of around US$ 400 billion a year are a major challenge from a
socioeconomic perspective [32], especially considering the
fact that TBI-related healthcare costs are rising, while
healthcare budgets remain limited [19]. The in-hospital costs
related to TBI represent a substantial part of the total utilised
resources [49]. Unfortunately, understanding and generalising
the in-hospital costs of individual TBI patients from available
literature remains difficult because methodological heteroge-
neity of TBI cost studies is high and study quality often inad-
equate [1, 30, 69].
Accurate insight in TBI-related costs is essential to substan-
tiate research initiatives that aim to improve treatment effi-
ciency. It also guides policymakers on the rational allocation
of resources without compromise of patient outcome. To al-
low healthcare professionals to continue to provide optimal
care for their patients, high-quality cost-analysis studies are
urgently needed [1, 30].
Therefore, the aim of this study is to describe outcome, in-
hospital healthcare consumption and in-hospital costs of
hospitalised TBI patients.
Materials and methods
This study followed the recommendations from the
‘Strengthening the Reporting of Observational Studies in
Epidemiology’ STROBE statement [76].
Study design and patients
Patients were included in three level 1 trauma hospitals from
January 2015 to September 2017. All hospitals are located in an
urban area in the mid-Western part of the Netherlands and
participated in the Collaborative European NeuroTrauma
Effectiveness Research in Traumatic Brain Injury (CENTER-
TBI) project. The CENTER-TBI Core study (clinicaltrials.gov
NCT02210221; RRID: SCR_015582) is a prospective
multicentre longitudinal observational study conducted in 65
centres across Europe and Israel [31]. The project aimed to
improve TBI characterisation and classification and to
identify best clinical care. The responsible institutional review
board (METC Leiden) approved this study (P14.222).
Patients were included in the CENTER-TBI Core study
using the following criteria: (1) clinical diagnosis of TBI, (2)
clinical indication for head CT scan, (3) presentation to study
centre within 24 h after injury and (4) informed consent fol-
lowing Dutch requirements, including patient, proxy and de-
ferred consent. Patients were excluded when they had a severe
pre-existing neurological disorder that would confound out-
come assessments or in case of insufficient understanding of
the Dutch or English language.
Clinical data
Clinical data were prospectively collected by using a web-
based electronic case report form (CRF) (QuesGen System
Incorporated, Burlingame, CA, USA). Data were obtained
from electronic patient files and patient interviews and when
necessary initially recorded on a hardcopy CRF. Data collec-
tion was completed by a local research staff that was specifi-
cally trained for this project. The site’s principal investigator
supervised the project. Data were de-identified by using a
randomly generated GUPI (Global Unique Patient Identifier)
and was stored on a secure database, hosted by the
International Neuroinformatics Coordinating Facility (INCF;
www.incf.org) in Stockholm, Sweden.
Data was extracted in December 2019 (version 2.1) using a
custom-made data access tool Neurobot (http://neurobot.incf.
org), developed by INCF (RRID: SCR_01700). Extracted data
included baseline demographic, trauma and injury information,
results of neurological assessments, imaging (first head CT scan)
and patient outcome. This database was merged with separately
collected data on in-hospital healthcare consumption and in-
hospital costs, which is explained later. Discrepancies were re-
solved by source data verification.
Baseline Glasgow Coma Scale (GCS) Total Score, GCS
Motor Score and pupillary reactivity variables were collected.
TBI severity was then classified by using the GCS (GCS13–
15; mild TBI, GCS9–12; moderate TBI, GCS3–8; severe TBI,
GCS3–5; very severe TBI) [64]. These values were derived
variables that were centrally calculated using the IMPACT
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methodology, taking a post stabilisation value and if absent
work back in time towards prehospital values. Out of 19 miss-
ing GCS values, 8 were completed by using emergency de-
partment arrival GCS score. Intubation was calculated as a
GCS verbal score of 1. Major extracranial injury was defined
by AIS body region ≥ 3. Characteristics from the first head CT
scan were assessed by a central review panel [73]. Six out of
seven missing central assessments were completed by using
the assessments of local radiologists. Outcome data included
in-hospital mortality and 6-month Glasgow Outcome Score–
Extended (GOSE). GOSE outcome was dichotomised in
favourable (GOSE ≥ 5) and unfavourable (GOSE ≤ 4) [78].
In-hospital healthcare consumption
We collected in-hospital healthcare consumption data from
electronic patient records by using a predefined cost assess-
ment database. The Dutch National Health Care Institute
Guidelines for healthcare cost calculation were followed
[23]. Units (e.g. number of admission days, number of diag-
nostics) were collected independently by two researchers from
the electronic patient files. There were five main categories:
(1) admission; including length of stay (LOS) in (non-)ICU
with consultations, (2) surgical interventions, (3) imaging, (4)
laboratory; including blood products and (5) other; including
ambulance transportation and outpatient visits [70]. Non-ICU
admission was defined as admission to a ward or medium
care. In-hospital healthcare consumption and costs were cal-
culated for all included patients (Supplement 1).
In-hospital costs
We focused on the in-hospital costs from a healthcare perspec-
tive. Costs of re-admissions and costs of visits to the
Outpatient Clinic related to the trauma were also included.
The methods and reference prices as described in the Dutch
Guidelines for economic healthcare evaluations were used to
calculate in-hospital costs [23]. Costs were calculated by mul-
tiplying the number of consumed units with the corresponding
guideline reference price. Guideline reference prices are based
on non-site specific large patient cohorts which improves their
generalisability and interpretation [23]. When reference prices
were not mentioned, the remaining units were valued by using
amounts per unit as reported by The Netherlands Healthcare
Authority (NZa) (i.e. diagnostics) [83] or by using their aver-
age national price, based on declared fees (i.e. surgical inter-
ventions, consultations) [82]. All costs were converted to the
last year of patient inclusion (2017) using the national general
consumer price index (CBS) and rounded to the nearest ten
euros. One EURO equalled $1.05 dollar on the 1st of January
2017 (Supplement 1).
Statistical methods
Data were analysed using descriptive statistics. Baseline data
were presented as absolute numbers and percentages.
Continuous variables, like LOS and costs, were presented as
mean ± standard deviation or median (interquartile range 25–
75). Subgroups were made using age, TBI severity, pupillary
abnormalities, intracranial abnormalities, surgical intervention
and outcome. ANOVA and χ2 were used for comparison of
continuous and categorical variables across different sub-
groups. A p value of < 0.05 was considered statistically sig-
nificant. All analyses were performed using IBM’s statistical
package for social sciences version 25.0 (SPSS). Figures were
designed using GraphPad Prism 8.
Results
A total of 486 patients with TBI were included in this study.
Patients had a mean age of 56.1 ± 22.4 years and were pre-
dominantly male (60.5%) (Table 1). Nearly all patients
sustained a closed head injury (98.4%). TBI was mainly
caused by incidental falls (54.3%) or road traffic accidents
(36.2%) and occurred on streets (56.2%) or at home
(31.5%). The mean baseline GCS was 12.7 ± 3.8 and mean
injury severity score (ISS) was 20 ± 16. Patients sustained
mild TBI (N = 354, 72.8%), moderate TBI (N = 43, 8.8%)
and severe TBI (N = 78, 16.1%), of which 51 were very severe
(10.5%). Loss to follow-up was 14.2% and not significantly
different between severity groups.
Patient outcome
Mean in-hospital mortality was 12.3% and ranged from 2.3%
for patients with mild TBI to 62.7% for patients with very
severe TBI (Table 1). The 6-month GOSE follow-up was
available for 417 patients (85.8%). Favourable outcome
(GOSE ≥ 5) was achieved by 85.4% of patients with mild,
55.3% with moderate, 29.0% with severe and 19.6% with
very severe TBI (Fig. 1). A GOSE of 2–4 was found in 40
survivors (8.2%), of which 17 (3.5%) were in a vegetative
state (GOSE = 2) or required full assistance in daily life
(GOSE = 3). Nearly a third of patients reported full recovery
(GOSE = 8) after mild (32.5%), 18.6% after moderate, 6.4%
after severe and 5.9% after very severe TBI.
Length of stay and surgical interventions
Mean total LOS was 8 days (2 days on ICU and 6 days non-
ICU). LOS significantly increased with TBI severity, presence
of major extracranial injury, surgical intervention(s) and pres-
ence of all types of intracranial abnormalities except epidural
hematoma (Table 2, Fig. 2). Patients that required ICP
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Table 1 Patient characteristics and outcome
All (N = 486) Mild TBI (N = 354) Moderate TBI (N = 43) Severe TBI (N = 78) Very severe TBI (N = 51) p value*
Male 294 (60.5) 211 (59.6) 25 (58.1) 54 (69.2) 36 (70.6) 0.265
Age (years) 56.1 ± 22.4 56.6 ± 22.2 58.5 ± 22.4 52.2 ± 22.6 50.9 ± 23.3 0.222
≤ 18 25 (5.1) 21 (5.9) 1 (2.3) 2 (2.6) 2 (3.9) 0.467
19–64 255 (52.5) 184 (52.0) 21 (48.8) 46 (59.0) 30 (58.8)
≥ 65 206 (42.4) 149 (42.1) 21 (48.8) 30 (38.5) 19 (37.3)
Stratum < 0.001
Admission 319 (65.6) 288 (81.4) 16 (37.2) 9 (11.5) 5 (9.8)
ICU 167 (34.4) 66 (18.6) 27 (62.8) 69 (88.5) 46 (90.2)
Location of injury 0.137
Street/highway 273 (56.2) 201 (56.8) 22 (51.2) 45 (57.7) 31 (60.8)
Home/domestic 153 (31.5) 113 (31.9) 11 (25.6) 25 (32.1) 15 (29.4)
Work/school 14 (2.9) 8 (2.3) 5 (11.6) 1 (1.3) 1 (2.0)
Sport/recreational 18 (3.7) 14 (4.0) 2 (4.7) 1 (1.3) 0 (0.0)
Public location 25 (5.1) 15 (4.2) 3 (7.0) 6 (7.7) 4 (7.8)
Other/unknown 2 (0.6) 3 (0.9) 0 (0.0) 0 (0) 0 (0.0)
Cause of injury 0.136
Road traffic accident 176 (36.2) 125 (35.3) 14 (32.6) 35 (44.9) 25 (49.0)
Incidental fall 264 (54.3) 200 (56.5) 21 (48.8) 35 (44.9) 20 (39.2)
Non-intentional injury 12 (2.5) 8 (2.3) 2 (4.7) 1 (1.3) 1 (2.0)
Violence/assault 10 (2.1) 8 (2.3) 2 (4.7) 0 (0.0) 0 (0.0)
Suicide attempt 3 (0.6) 0 (0.0) 1 (2.3) 2 (2.6%) 2 (3.9)
Other/unknown 21 (4.3) 13 (3.6) 3 (7.0) 5 (6.4) 3 (5.9)
Glasgow Coma Score 12.7 ± 3.8 14.7 ± 0.6 10.6 ± 0.9 4.7 ± 1.9 3.5 ± 0.7 N/A
GCS Motor score 5.3 ± 1.6 6.0 ± 0.4 5.0 ± 1.3 2.3 ± 1.7 1.4 ± 0.8
GCS 13–15 354 (72.8) 354 (100) – – –
GCS 9–12 43 (8.8) – 43 (100) – –
GCS 3–8 78 (16.1) – – 78 (100) –
GCS 3–5 51 (10.5) – – 51 (65.4) 51 (100)
Missing 11 (2.3) – – – –
Pupillary abnormalities < 0.001
Both reacting 423 (87.0) 343 (98.0) 39 (90.7) 38 (48.7) 19 (37.3)
One reacting 14 (2.9) 5 (1.4) 2 (4.7) 7 (9.0) 4 (7.8)
Both non-reacting 37 (7.6) 2 (0.6) 2 (4.7) 33 (42.3) 28 (54.9)
Missing 12 (2.5) 4 (1.1) 0 (0.0) 0 (0.0) 0 (0.0)
Findings first CT scan
Intracranial abnormalities 263 (54.1) 160 (45.2) 30 (69.8) 68 (87.2) 43 (84.3) < 0.001
Contusion 130 (26.7) 68 (19.2) 22 (51.2) 38 (48.7) 26 (51.0) < 0.001
Traumatic SAH 185 (38.1) 101 (28.5) 26 (60.5) 56 (71.8) 37 (72.5) < 0.001
Epidural hematoma(s) 47 (9.7) 27 (7.6) 7 (16.3) 13 (16.7) 9 (17.6) < 0.001
Subdural hematoma(s) 136 (28.0) 68 (19.2) 22 (51.2) 43 (55.1) 28 (54.9) < 0.001
Skull fracture(s) 180 (37.0) 97 (27.4) 25 (58.1) 55 (70.5) 39 (76.5) < 0.001
Compressed basal cisterna 88 (18.1) 30 (8.5) 9 (20.9) 47 (60.3) 34 (66.7) < 0.001
Midline shift > 5 mm 65 (13.4) 21 (5.9) 10 (23.3) 31 (39.7) 20 (39.2) < 0.001
Mass lesion > 25 cc 80 (16.5) 26 (7.3) 14 (32.6) 37 (47.4) 26 (51.0) < 0.001
Uninterpretable** 10 (2.1) 5 (1.4) 4 (9.3) 0 (0.0) 0 (0.0)
Injury severity
Brain Injury AIS 3.1 ± 1.2 2.7 ± 0.9 3.7 ± 1,2 4.6 ± 1.2 4.8 ± 1.2 < 0.001
ISS 20 ± 16 15 ± 9 22 ± 16 39 ± 22 43 ± 21 < 0.001
In-hospital mortality 60 (12.3) 8 (2.3) 8 (18.6) 42 (53.8) 32 (62.7) < 0.001
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monitoring and/or a decompressive craniectomy showed lon-
gest mean LOS (27 and 28 days respectively). LOS was short
in patients without intracranial abnormalities (5 days). Patients
with two non-reacting pupils also showed a significantly
shorter LOS (5 days) compared with those with either one
(17 days) or two reacting pupils (8 days).
A total of 126 patients (27.2%) received a surgical inter-
vention, of which 67 intracranial (13.8%) and 65 extracranial
(13.4%). Intracranial surgery was significantly more common
in more severely injured TBI subgroups (6.2% for mild,
34.9% for moderate and 35.9% for severe TBI) (Table 2).
In-hospital costs
Mean in-hospital costs were €11,918. €7896 was related to
admission (66%), €1493 to surgery (13%) and €1042 to other
(9%) (Table 2). Costs related to radiology (7%) and laboratory
(5%) were smaller contributors. Average in-hospital costs
were €7795 for mild, €20,207 for moderate €26,595 for severe
and €26,349 for very severe TBI patients (Fig. 2). Presence of
intracranial abnormalities on the first CT scan nearly doubled
total in-hospital costs (€15,783 vs. €8238). Intracranial sur-
gery or ICP monitoring quadrupled the costs (respectively
€36,866 vs. €7928 and €47,255 vs. €8748). Patients with a
decompressive craniectomy (€49,754), ‘regular’ craniotomy
(€33,195) or extracranial surgery (€19,957) were also more
expensive compared with non-surgically treated patients.
Patients with a 6-month GOSE score of 8 showed the lowest
in-hospital costs of € 5774, while patients with a GOSE score
of 2/3 showed costs of €36,190.
Discussion
The current study found substantial in-hospital healthcare con-
sumption and high in-hospital costs for hospitalised TBI pa-
tients, even after mild TBI. Both length of stay and in-hospital
costs increased with TBI severity and presence of intracranial
abnormalities and extracranial injuries. The most important
cost drivers were admission and surgical intervention.
Patients from all TBI severity categories were able to achieve
full recovery, even after sustaining very severe TBI.
Nonetheless, mortality and unfavourable outcome rates were
high and the majority of patients reported remaining deficits or
disabilities after 6 months.
Fig. 1 In-hospital mortality and functional outcome (favourable GOSE
5–8, unfavourable GOSE 1–4) at 6 month follow-up for patients with TBI
in different severities
Table 1 (continued)
All (N = 486) Mild TBI (N = 354) Moderate TBI (N = 43) Severe TBI (N = 78) Very severe TBI (N = 51) p value*
GOSE at 6 months 5.72 ± 2.55 6.5 ± 1.8 4.6 ± 2.7 2.9 ± 2.7 2.4 ± 2.5
Favourable/unfavourable*** 72.9%/27.1% 85.4%/14.6% 55.3%/44.7% 29.0%/71.0% 19.6%/80.4% < 0.001
1 73 (15.0) 15 (4.2) 10 (23.3) 45 (57.7) 34 (66.7) < 0.001
2/3 17 (3.5) 10 (2.8) 6 (14.0) 1 (1.3) 0 (0.0)
4 23 (4.7) 19 (5.4) 1 (2.3) 3 (3.8) 3 (5.9)
5 25 (5.1) 18 (5.1) 5 (11.6) 2 (2.6) 1 (2.0)
6 38 (7.8) 31 (8.8) 4 (9.3) 3 (3.8) 1 (2.0)
7 110 (22.6) 93 (26.3) 4 (9.3) 10 (12.8) 4 (7.8)
8 131 (27.0) 115 (32.5) 8 (18.6) 5 (6.4) 3 (5.9)
Loss to follow-up 69 (14.2) 53 (15.0) 5 (11.6) 9 (11.5) 5 (9.8) 0.650
Values are reported as: Number (percentage). Mean ± SD. AIS, abbreviated injury scale; CT scan, computed tomography scan; GCS, Glasgow Coma
Score; GOSE, Glasgow Outcome Score–Extended; ICU, intensive care unit; SAH, subarachnoid haemorrhage
* p values were derived from ANOVA for continuous characteristics and χ2 statistics for categorical characteristics, comparing TBI severity categories
(severe TBI, moderate TBI, mild TBI). The p value assessed compatibility with the null hypothesis of no differences between TBI severity categories
** Numbers from TBI severity subgroups do not always match the numbers that are reported for all patients because baseline GCS data was missing for
11 patients. Also, data from 1 CT scan could not be retrieved
***Calculated excluding missing. Favourable and unfavourable were defined as GOSE 5–8 and GOSE 1–4 respectively
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Study cohort
The predominance of male gender, injury mechanisms (road traf-
fic accidents and falls) and distribution of TBI severity were in
accordance with recent literature [7, 15, 29, 33]. The mean age of
56 years was rather high compared to earlier research [7], but
matched changing epidemiological patterns [32]. The number of
intracranial CT abnormalities in mild TBI patients was higher
compared with that in literature (45.2% vs. 16.1%) [26]. This is
likely caused by different inclusion criteria (hospital admission
after TBI vs. ED presentation with head CT after suspected TBI)
and differences in accuracy between central and local radiological
reading [73]. The number of patientswithmajor extracranial injury
(AIS≥ 3) and pupillary abnormalities was also higher compared
with that in literature [72, 77] and the overall CENTER-TBI Core
study cohort [59]. These factors, with other factors like comorbid-
ities and use of anticoagulants, could have negatively influenced
patient outcome and/or increased the reported in-hospital
healthcare consumption and in-hospital costs in this study.
Patient outcome
Mortality rates were generally high, but difficult to com-
pare with other studies due to methodological differences
[16, 32, 51]. One meta-analysis reported higher ‘all time
point’ mortality rates for patients of all TBI severities
[38], while other studies showed lower mortality rates
for mild TBI [10], moderate TBI [16] and severe TBI
[51, 58]. Favourable outcome (6-month GOSE) rates were
generally higher in literature [39, 51, 16]. Differences in
patient outcome can largely be explained by patient relat-
ed factors that are known to be associated with worse
outcome. Such factors include higher age, higher injury
severity, poorer initial neurologic condition and higher
TBI severity (defined by GCS) and are reported above
average in our cohort [28, 38, 71]. For instance, the in-
clusion of patients with a GCS = 3 and/or bilateral pupil-
lary abnormalities influences the comparison of patient
outcome, as they are typically excluded in literature
because of their often-perceived dismal prognosis [65].
Even the most severely injured patients that were able to
achieve favourable outcome and even full recovery, al-
though rarely, has been reported previously [71].
The increase in mortality rates (12.3 to 15%) and data
on persisting deficits and disabilities after 6 months con-
firm the need for increased vigilance and attention for
rehabilitation or long-term care opportunities. Sustained
health problems after TBI have also been reported by
long-term follow up studies [21, 42, 52, 74], some
reporting deterioration between 5 and 10 years [17], others
reporting remaining functional limitations up to 20 years
after moderate and severe TBI [3]. Long-term impairments
are not limited to severe TBI, but are also reported after
mild TBI [14, 68]. Despite the short 6-month follow-up,
our results support statements that consider TBI to be an
acute injury resulting into a chronic health condition that
requires continued care for most patients. TBI should
therefore be addressed as such by healthcare providers,
researchers and policymakers [60, 79].
Length of stay
Healthcare consumption in terms of length of stay and
surgical intervention was substantial. However, when
comparing our overall results to numbers for patients
(age < 65) from Canada, our mean LOS (days) was shorter
for all patients (8 vs. 13), for patients with mild TBI (6 vs.
9) and severe TBI (15 vs. 22) but similar for moderate TBI
(14 vs. 14) [62]. Median LOS was also shorter for mild
TBI (3 vs. 9), moderate TBI (7 vs. 11) and severe TBI (7
vs. 12) compared with recent numbers from England and
Wales [29]. In a review on hospital costs for severe TBI
patients, total LOS ranged between 10 and 36.8 days and
ICU LOS between 7.9 and 25.8 days [69]. The large
ranges are exemplary for the existing variation, that is,
primarily caused by patient case-mix and treatment-
related factors [40]. Several factors that we found to be
associated with an increased total LOS were also men-
tioned in literature: lower GCS, higher TBI severity and
the presence of extracranial injury [13, 62], ICP monitor-
ing [46, 61] and decompressive craniectomy [27, 53].
There were several exceptions. For instance, the most
severely injured TBI patients were sometimes admitted to
the ward because of treatment limiting decisions shortly
after presentation [50]. This could explain the lower LOS
and lower in-hospital costs for very severe TBI patients
and patients with two non-reacting pupils. Similarly, some
mild TBI patients could have been admitted to the ICU
because of (suspected) deterioration or over-triage or non-
TBI related issues such as age, comorbidities, and con-
comitant extracranial injuries [6, 36].
Fig. 2 The mean in-hospital costs for patients with TBI, specified per
severity category and per cost category to show their contribution to the
total in-hospital costs
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In-hospital costs
The median costs and interquartile range indicate that costs were
skewed by a small group of patients with very high costs. The
reported costs were generally similar to available literature. One
Dutch study reported that the direct and indirect costs for all TBI
patients were €18,030 [56]. Costs were higher for Dutch patients
with severe TBI (range €40,680–€44,952), but these costs in-
cluded rehabilitation and nursing home costs [55]. A recent sys-
tematic review reported median in-hospital costs per patient with
severe TBI of €55,267 (range €2130 to €401,808) [69]. Mean
hospital and healthcare charges for TBI in the USA were
$36.075 and $67.224 respectively [2, 35]. Differences between
studies could be explained by variation, methodological hetero-
geneity, differences in case mix, but also by geographical loca-
tion. For example, healthcare expenditures in the USA are gen-
erally double of other high-income countries due to prices of
labour, goods, pharmaceuticals and administrative costs, while
healthcare utilisation was similar [45]. These issues are also re-
ported in non-TBI literature [12, 47].
As in other studies, the main cost drivers in this current
study were LOS and/or admission (66%), surgery (12%), ra-
diology (7%), labs (4%) and other costs (11%) [2, 41, 81]. In-
hospital costs were generally higher for the more severely
injured patients [35, 41], with a lower GCS [24, 41, 48, 63,
69] or pupillary abnormalities [70]. Higher costs were related
to an increased healthcare consumption with longer LOS [2,
48], specialised intensive care unit (ICU) treatment [2] and a
more frequent use of ICP monitoring [37, 61, 81] and surgical
procedures [41, 70, 80]. The presence of TBI normally in-
creases the LOS of general admissions [62], but extracranial
injury and higher overall injury severity in addition to TBI
also contributed to higher in-hospital healthcare consumption
and in-hospital costs [13, 57, 80]. It is however impossible to
distinguish costs related to extracranial injury from costs re-
lated to TBI because these costs are too intertwined.
Compared with the hospital costs for other diseases in the
Netherlands, the in-hospital costs for TBI patients were high,
especially when TBI severity increased. The hospital costs for
patients with ischaemic stroke (€5.328) [8], transient ischaemic
attack (€2.470) [8], appendicitis (€3700) and colorectal cancer
(€9.777–€19.417) [20] were lower, while costs were higher for
patientswith non-small cell lung cancer (€33.143) [67] or patients
receiving extracorporeal life support treatment (€106.263) [44].
Strengths and limitations
The accurate calculation of in-hospital healthcare consumption and
in-hospital costs of a large prospective multicentre cohort is a
strength of the current study. There are also several limitations.
The GCS is usually used to determine TBI severity [7], but its
general applicability as a severitymeasure is also criticised [5]. The
GCS could have been influenced by intoxication, pharmacological
sedation, prehospital intubation, extracranial injury and could
thereby have over- and underestimated injury severity [54]. This
could have influenced study results. In a similar way, patient out-
come was measured by using in-hospital mortality and GOSE.
Critics state that the GOSE insufficiently accounts for the multidi-
mensional nature of TBI outcome [32]. Unfortunately, earlier re-
ported problems with acquiring the disease related health related
quality of life outcome measure QOLIBRI resulted in too many
missing data points to be useful for this manuscript [70]. Another
limitation is the short-term follow-up because it is known that
patient outcome and costs can change over time [17, 60, 79].
TBI patients that visited the ER but did not require hospitalisation
were not included in this study. A precise calculation and compar-
ison of costs was therefore not possible. Costs of these patients are
expected to be substantially lower compared with those of admit-
ted patients since important cost drivers (admission and surgery)
are not applicable. Following the unit costs in Supplement 1 (ER,
imaging, labs), the average costs are likely to be somewhere be-
tween €500 and €1.000. A reduction in number of admitted mild
TBI patients, when safe and possible, might result in substantial
cost savings, especially since its incidence is high.
The direct costs of TBI (all consumed resources within the
health-care sector) are generally considered to be smaller than the
indirect costs (loss of productivity and intangible costs) [22, 32,
43]. Because of the focus on in-hospital costs, our study results
dramatically underestimate the exact total costs related to TBI
[34, 56, 66]. The reported in-hospital costs are also likely to be an
underestimation, despite our accurate calculations.More accurate
numbers could be achieved by using hospitals’ actual cost prices,
rather than approximations from guidelines or governmental or-
ganisations. These numbers were unfortunately unavailable.
Including an accurate complete cost overview is however essen-
tial for future cost-effectiveness studies [11, 34, 48, 66].
Future TBI research initiatives should include the combination
of long-term outcome and complete economic perspective, be-
cause this can improve the objectivity of future treatment deci-
sion-making. When striving for cost-effectiveness, people should
however not forget the individual aspects of care and the social
utility of providing care for severely injured patients [25].
Conclusion
Hospitalised TBI patients show substantial in-hospital healthcare
consumption and high in-hospital costs, even in patients with
mild TBI. These costs are likely to be an underestimation of
the actual total costs after TBI. Although patients from all TBI
severity categories were able to achieve full recovery, mortality
and unfavourable outcome rates were high and increased with
TBI severity, intracranial abnormalities, extracranial injury and
surgical intervention. Future studies should focus on the long-
term effectiveness of treatments in relation to a complete eco-
nomic perspective.
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